DeepMed Research

BAUSCH HEALTH AMERICAS, INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: 3.1K

Market Cap: -

Website: http://www.bauschhealth.com

Clinical Trials

An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects

Phase 4

Recruiting

Conditions: Psoriasis

Interventions: Biological: Brodalumab

First Posted Date: 2017-08-07

Last Posted Date: 2023-08-14

Lead Sponsor: Bausch Health Americas, Inc.

Target Recruit Count: 16

Registration Number: NCT03240809

Locations: 🇺🇸
Bausch Site 005, Henderson, Nevada, United States
🇺🇸
Bausch Site 003, San Diego, California, United States
🇺🇸
Bausch Site 002, Miami, Florida, United States

and more 2 locations

A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle Controlled, Parallel-Group, Clinical Study in the Treatment of Acne Vulgaris

Phase 2

Completed

Conditions: Acne Vulgaris

Interventions: Drug: IDP-126 Vehicle Gel
Drug: IDP-126 Gel
Drug: IDP-126 Component A
Drug: IDP-126 Component B
Drug: IDP-126 Component C

First Posted Date: 2017-05-31

Last Posted Date: 2021-11-10

Lead Sponsor: Bausch Health Americas, Inc.

Target Recruit Count: 741

Registration Number: NCT03170388

Locations: 🇺🇸
Valeant Site 22, Detroit, Michigan, United States
🇺🇸
Valeant Site 31, Nashville, Tennessee, United States
🇺🇸
Valeant Site 26, New York, New York, United States

and more 31 locations

A Phase 3, Vehicle-controlled Efficacy and Safety Study of IDP-123 Lotion in the Treatment of Acne Vulgaris (301)

Phase 3

Completed

Conditions: Acne Vulgaris

Interventions: Drug: IDP-123 Lotion
Drug: IDP-123 Vehicle Lotion

First Posted Date: 2017-05-30

Last Posted Date: 2021-04-01

Lead Sponsor: Bausch Health Americas, Inc.

Target Recruit Count: 813

Registration Number: NCT03168321

Locations: 🇺🇸
Valeant Site 27, Pembroke Pines, Florida, United States
🇺🇸
Valeant Site 36, New York, New York, United States
🇺🇸
Valeant Site 26, Newnan, Georgia, United States

and more 42 locations

A Phase 3, Vehicle-controlled Efficacy and Safety Study of IDP-123 Lotion in the Treatment of Acne Vulgaris (302)

Phase 3

Completed

Conditions: Acne Vulgaris

Interventions: Drug: IDP-123 Lotion
Drug: IDP-123 Vehicle Lotion

First Posted Date: 2017-05-30

Last Posted Date: 2021-04-01

Lead Sponsor: Bausch Health Americas, Inc.

Target Recruit Count: 801

Registration Number: NCT03168334

Locations: 🇺🇸
Valeant Site 39, Sugar Land, Texas, United States
🇺🇸
Valeant Site 07, Dallas, Texas, United States
🇺🇸
Valeant Site 33, Stony Brook, New York, United States

and more 42 locations

An Efficacy and Safety Study of Plecanatide in Adolescents 12 to <18 Years of Age With Chronic Idiopathic Constipation

Phase 2

Completed

Conditions: Chronic Idiopathic Constipation

Interventions: Drug: Plecanatide
Drug: Matching placebo

First Posted Date: 2017-04-19

Last Posted Date: 2019-10-04

Lead Sponsor: Bausch Health Americas, Inc.

Target Recruit Count: 124

Registration Number: NCT03120520

Locations: 🇺🇸
Synergy Research Site, Newport News, Virginia, United States

Evaluation of the Safety, Systemic Pharmacokinetics, and Tolerability

Phase 1

Completed

Conditions: Eye Pain

Interventions: Drug: Loteprednol Etabonate Ophthalmic Gel

First Posted Date: 2017-02-24

Last Posted Date: 2017-02-24

Lead Sponsor: Bausch Health Americas, Inc.

Target Recruit Count: 15

Registration Number: NCT03063489

Locations: 🇺🇸
Valeant Site 03, Oceanside, California, United States
🇺🇸
Valeant Site 05, Miami, Florida, United States
🇺🇸
Valeant Site 06, Kansas City, Missouri, United States

and more 3 locations

Efficacy and Safety of IDP-124 Lotion for the Treatment of Moderate to Severe Atopic Dermatitis in Pediatric and Adult Subjects

Phase 3

Completed

Conditions: Atopic Dermatitis

Interventions: Drug: IDP-124 Lotion
Drug: IDP-124 Vehicle Lotion

First Posted Date: 2017-02-23

Last Posted Date: 2023-05-08

Lead Sponsor: Bausch Health Americas, Inc.

Target Recruit Count: 328

Registration Number: NCT03058783

Locations: 🇺🇸
Valeant Site 05, Fremont, California, United States

Topically Applied IDP-118 Lotion and HP Monad Lotion in Subjects With Moderate to Severe Plaque Psoriasis

Phase 1

Completed

Conditions: Psoriasis

Interventions: Drug: IDP-118 Lotion
Drug: HP Monad Lotion
Drug: Ultravate Cream
Drug: Tazorac Cream

First Posted Date: 2017-02-23

Last Posted Date: 2017-06-09

Lead Sponsor: Bausch Health Americas, Inc.

Target Recruit Count: 94

Registration Number: NCT03058744

Locations: 🇺🇸
Valeant Site 05, Encino, California, United States
🇺🇸
Valeant Site 06, New York, New York, United States
🇺🇸
Valeant Site 01, San Diego, California, United States

and more 9 locations

Efficacy and Safety of IDP-120 Gel in the Treatment of Acne Vulgaris

Phase 2

Completed

Conditions: Acne Vulgaris

Interventions: Drug: IDP 120 Vehicle Gel
Drug: IDP-120 Gel
Drug: IDP 120 Component A Gel
Drug: IDP 120 Component B Gel

First Posted Date: 2016-12-26

Last Posted Date: 2017-12-18

Lead Sponsor: Bausch Health Americas, Inc.

Target Recruit Count: 364

Registration Number: NCT03003247

Locations: 🇺🇸
Valeant Site 15, Encino, California, United States
🇺🇸
Valeant Site 13, Lake Mary, Florida, United States
🇺🇸
Valeant Site 14, Tampa, Florida, United States

and more 21 locations

Efficacy and Safety of IDP-124 Lotion for the Treatment of Moderate to Severe Atopic Dermatitis in Pediatric and Adult Subjects (301)

Phase 3

Completed

Conditions: Atopic Dermatitis

Interventions: Drug: IDP-124 Vehicle Lotion
Drug: IDP-124 Lotion

First Posted Date: 2016-12-23

Last Posted Date: 2023-05-08

Lead Sponsor: Bausch Health Americas, Inc.

Target Recruit Count: 338

Registration Number: NCT03002571

Locations: 🇺🇸
Valeant Site 01, Fort Lauderdale, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy